You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大行評級|建銀國際:下調康方生物目標價至56.2港元 維持“跑贏大市”評級 指市場過度反應
格隆匯 05-28 15:06
建銀國際發表研究報吿指,康方生物上週公佈旗下藥物AK112的臨牀數據不如預期,股價隨即下跌約35%,認為是市場過度反應,未有考慮AK112在臨牀取得的其他成功,包括提前獲批另一種適應症,也沒有考慮到康方生物如AK104等其他藥物。報吿指,在公司股價大跌的同日,AK112與化療聯合治療的藥物提前獲內地批准上市,用於治療NSCLC患者。因此,該行分別上調AK112在2024年至2026年的銷售額預測16%、5%及17%至3.86億元、14億元及18億元,亦將該藥物的最高銷售額由51億元上調至58億元,並在2029年末達到。為了反映AK112在2025年至2026年所需的商業化、推廣和銷售成本,該行將2024年至2026年的支出佔銷售預測比率分別上調10個、10個及8個百分點,並將2024年的調整後淨虧損預測從虧損4.39億元向下調整至虧損5.98億元。而且,該行亦將2025年的調整後淨利潤預測從6.06億元下調至1.66億元,將2026年的調整後淨利潤預測從18億元下調至14億元。該行將公司目標價由59港元降至56.2港元,維持“跑贏大市”評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account